Liminatus Pharma, Inc. (LIMN)

NASDAQ: LIMN · Real-Time Price · USD
6.27
-0.51 (-7.52%)
At close: Jul 31, 2025, 4:00 PM
6.30
+0.03 (0.48%)
After-hours: Jul 31, 2025, 7:59 PM EDT
-7.52%
Market Cap163.11M
Revenue (ttm)n/a
Net Income (ttm)-3.55M
Shares Out 26.01M
EPS (ttm)-0.14
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume213,654
Open6.62
Previous Close6.78
Day's Range6.10 - 6.84
52-Week Range4.40 - 33.66
Beta0.57
Analystsn/a
Price Targetn/a
Earnings Daten/a

About CTIC

Liminatus Pharma, Inc. operates as a pre-clinical stage biopharmaceutical company that develops novel cancer therapies. It is developing CD47, a high affinity humanized anti CD47 antibody that has the potential to translate into clinic for CD47 SIRPα blocking and restoring the anti-tumor function of innate immune cells without inducing hemagglutination or hemolysis. The company was founded in 2018 is based in LA Palma, California. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Country United States
Stock Exchange NASDAQ
Ticker Symbol LIMN
Full Company Profile

Financial Performance

Financial Statements

News

Liminatus Pharma Inc. to Launch “American BNB Strategy” Subsidiary and Target Up To $500 Million Fund for BNB Investment as Part of Crypto Market Initiative

Liminatus Identifies BNB Coin as Its Primary Strategic Target for Digital Asset Allocation, with Plans to Aggressively Accumulate and Hold Up to $500 Million for Long-Term Strategic Value Liminatus Id...

3 days ago - GlobeNewsWire

Liminatus Pharma Inc. Evaluates Formation of Digital Asset Investment Vehicle Targeting Up To $500 Million in Capital Strategies

Strategic Internal Review initiated for treasury diversification through a prospective digital asset subsidiary — no entity formed, no capital committed Strategic Internal Review initiated for treasur...

6 days ago - GlobeNewsWire

Liminatus Pharma Inc. Takes Next Step in Evaluating Digital Asset-Linked Capital Strategy

Agreement with Digital Offering Advances Company's plan to assess innovative treasury-backed financing paths Agreement with Digital Offering Advances Company's plan to assess innovative treasury-backe...

7 days ago - GlobeNewsWire

Liminatus Pharma, Inc. Initiates Strategic Review of Blockchain-Integrated Treasury Strategy

LA PALMA, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted cancer immunotherapies...

9 days ago - GlobeNewsWire